What factors influence the Healthcare/Pharma Sector?

Hello,
Looking to learn more about what influences the healthcare/pharma sector as I'm interested in investing in this space.
 

Is the healthcare sector sensitive to interest rates? My understanding is that most hospital systems are some version of a public private partnership. I'm not totally clear on how capital is structured to fund a hospital system. Is it a combination of municipal bonds and private equity?
 

I imagine that pharma companies are very sensitive to interest rates as they would utilize corporate bonds to raise capital for RD. I guess regulatory frameworks/government stance on drug approval timelines would also influence pharma?
 

If you know of any publications online related to this sector that would be helpful as well.

6 Comments
 
Most Helpful

Some big trends in healthcare are an aging population, changing regulatory/reimbursement landscape, and greater use of technology across the spectrum from drug development to delivery models.

Regarding your interest rate questions, I think you are really asking about cost of capital. A high dividend paying large cap pharma company may be able to fund an acquisition with relatively cheap investment grade debt; whereas a pre-revenue biotech company may be reliant on expensive/dilutive equity financing to fund operating losses. However, healthcare is so big that you will see a wide spectrum of financing used for different business models including muni bonds to build non-profit hospitals, HY debt / private credit for healthcare services roll-ups, and convertible debt or royalty deals in lieu of straight equity for biotech.

 

Under healthcare sector there are subsectors pharma, biotech, medical devices, hospitals and insurance. 

Healthcare Finance Journal is edited by an veteran investment banker focused on hospitals.

For an engineer I feel medical device subsector might be more relevant.

I agree with the comments made earlier especially the one about reimburesment issues. Awhile ago I shared a post with few articles on factors such as economic evaluation discussing their recent impact on biotech and pharma subsectors, one from the aformentioned journal but it did not get any comments. 

Sovereign Wealth Fund Consultant
 

Distinctio qui est ipsum et dolores optio. Commodi dolores voluptatibus possimus perspiciatis eius eaque. Ad suscipit ut officiis reiciendis rerum animi.

Career Advancement Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.3%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.2%

Overall Employee Satisfaction

July 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.9%
  • Morgan Stanley 01 98.3%
  • Banco Santander 02 97.7%
  • BMO Capital Markets 12 97.2%

Professional Growth Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 06 98.3%
  • Goldman Sachs 01 97.7%
  • JPMorgan 01 97.2%

Total Avg Compensation

July 2026 Investment Banking

  • Vice President (16) $429
  • Associates (46) $258
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (14) $159
  • 1st Year Analyst (80) $150
  • Intern/Summer Analyst (73) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
kanon's picture
kanon
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
Secyh62's picture
Secyh62
99.0
5
dosk17's picture
dosk17
98.9
6
GameTheory's picture
GameTheory
98.9
7
Betsy Massar's picture
Betsy Massar
98.9
8
CompBanker's picture
CompBanker
98.9
9
DrApeman's picture
DrApeman
98.9
10
numi's picture
numi
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”